Interestingly, osteopontin, secreted by cancer-associated mesothelial cells, has been shown to enhance chemoresistance and stemness in ovarian cancer by activating CD44 receptors, stimulating PI3K/AKT signaling, and increasing ABC transporter-mediated drug efflux [228]. This evidence concerns the gene AKT1 and ovarian cancer.